Healthcare
ProPhase Labs, Inc.(PRPH)
Live Price
Offline$0.08
-11.11% today
1Y Change
-97.79%
Window
Jun 23, 2025 โ Jun 17, 2026
- Market Cap
- โ
- Revenue Growth
- -84.7%
- EPS Growth
- -166.3%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 23, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ProPhase Labs, Inc. (PRPH) is a Healthcare stock with listed on NASDAQ. The stock last traded around $0.08 and down 97.8% across the available one-year price window (Jun 23, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of -84.7%, EPS growth of -166.3%, a dividend yield of 0.0%. What stands out right now is revenue -84.7%, EPS -166.3%, free cash flow -27.2% with operating margin -2496.6% and ROIC -156.9%. Valuation is more restrained than many high-expectation growth names at price/sales 0.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PRPH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-84.7% vs +7.6% peer median
Operating Margin
Below sector median
-2496.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 18, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -84.7% and EPS is at -166.3%, with operating margin around -2496.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -18.1% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 18, 2026 | โ | -9.1% | -18.2% | -27.3% |
2026 Apr 14, 2026 | โ | +7.1% | -14.3% | -7.1% |
2025 Nov 19, 2025 | -45.5% | -17.4% | -21.7% | -52.2% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PRPH
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PRPH Max Drawdown
-98.85%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PRPH and SPY.
Company Overview
ProPhase Labs, Inc.
NASDAQ Capital Market
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
- Leadership
- Ted William Karkus
- IPO Date
- Apr 4, 1994
- Employees
- 96
- Street Address
- 711 Stewart Avenue
- Mailing
- Garden City, NY, 11530
- Region
- Garden City, NY, US
- Reporting Currency
- USD
- Investor Line
- 215 345 0919
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.6
- Price/Book
- 0.1
Growth
- Revenue
- -84.7%
- EPS
- -166.3%
- Free Cash Flow
- -27.2%
Profitability
- Gross Margin
- 191.4%
- Operating Margin
- -2496.6%
- Net Margin
- -3872.2%
- ROE
- -404.4%
- ROIC
- -156.9%
Balance Sheet
- Debt/Equity
- 1.12
- Current Ratio
- 0.14
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.